Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of $0.14, $0.31 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $43.6 million versus the consensus estimate of $41.54 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.